Sign in

    Wim Gille • ABN AMRO-ODDO

    Wim Gille's questions to Koninklijke Philips NV (PHG) leadership

    Wim Gille's questions to Koninklijke Philips NV (PHG) leadership • Q1 2025

    Question

    Wim Gille challenged the CFO's statement that 'nothing changed,' arguing that the guidance implies an underlying performance improvement when accounting for tariffs. He also suggested Personal Health is outperforming expectations and asked for regional exit rates and the impact of any forward buying.

    Answer

    CFO Charlotte Hanneman clarified that the guidance change was driven by two factors: the new tariff impact and the better-than-expected Q1 performance. While pleased with the strong double-digit growth in Personal Health in international regions, she cautioned it is too early to deem the momentum sustainable. She reiterated that China's consumer demand remains subdued and U.S. growth was slight, with the main driver being international markets.

    Ask Fintool Equity Research AI

    Wim Gille's questions to Koninklijke Philips NV (PHG) leadership • Q4 2024

    Question

    Wim Gille asked for details on the higher-than-expected incidental charges in the Diagnosis & Treatment (D&T) segment, specifically the nature of the restructuring and which modalities were affected by quality actions.

    Answer

    CFO Charlotte Hanneman acknowledged the higher charges and attributed them to two main factors: proactive measures to resolve quality issues as part of the company's plan, and costs associated with footprint changes aimed at creating a leaner, less complex supply chain organization. She declined to provide specific details on which modalities were involved in the quality actions.

    Ask Fintool Equity Research AI